<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37047117</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24076144</ELocationID><Abstract><AbstractText>Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the generation of anti-DNA autoantibodies due to exposure of immune cells to excessive amounts of extracellular DNA. Lack of P-selectin in mice induces the development of a lupus-like syndrome and patients with cutaneous lupus have reduced P-selectin expression in skin vessels. Using flow cytometry we analyzed in healthy donors and patients the expression of P-selectin Glycoprotein Ligand-1 (PSGL-1) in circulating neutrophils and the implication of PSGL-1/P-selectin interaction in neutrophil extracellular traps (NETs) generation. We found a statistical significance that neutrophils from active SLE patients have a reduced expression of PSGL-1 and low levels of PSGL-1 in neutrophils from SLE patients associated with the presence of anti-dsDNA antibodies, clinical lung involvement, Raynaud's phenomenon, and positive lupus anticoagulant. PSGL-1 is present along the DNA in the NET. In healthy donors, neutrophil interaction with immobilized P-selectin triggers Syk activation, increases the NETs percentage and reduces the amount of DNA extruded in the NETs. In active SLE patients, neutrophil interaction with P-selectin does not activate Syk or reduce the amount of DNA extruded in the NETs, that might contribute to increase the extracellular level of DNA and hence, to disease pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Callejas</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-S&#xe1;nchez</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silv&#xe1;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Antonio</LastName><ForeName>Esther</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8667-7247</Identifier><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Tajuelo</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Manzano</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6376-058X</Identifier><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Abad</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2661-6367</Identifier><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Alvaro</LastName><ForeName>Isidoro</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9614-5199</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-P&#xe9;rez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0026-1043</Identifier><AffiliationInfo><Affiliation>Pulmonology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomero</LastName><ForeName>Eva G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vicu&#xf1;a</LastName><ForeName>Rosario Garc&#xed;a</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0001-9096-3780</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicente-Rabaneda</LastName><ForeName>Esther F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casta&#xf1;eda</LastName><ForeName>Santos</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7748-853X</Identifier><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Catedra UAM-Roche, EPID-Future, Department of Medicine, Universidad Aut&#xf3;noma de Madrid, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urzainqui</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9326-6112</Identifier><AffiliationInfo><Affiliation>Immunology Department, Fundaci&#xf3;n de Investigaci&#xf3;n Biom&#xe9;dica (FIB), Instituto de Investigaci&#xf3;n Sanitaria-Princesa (IIS-Princesa), Hospital de la Princesa, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FIS-PI17-01819</GrantID><Agency>Spanish Ministry of Health and ISCIII (co-financed by Fondos FEDER)</Agency><Country/></Grant><Grant><GrantID>FIS-PI20-01690</GrantID><Agency>Spanish Ministry of Health and ISCIII (co-financed by Fondos FEDER)</Agency><Country/></Grant><Grant><GrantID>EuroNanoMed III AC17-0027</GrantID><Agency>Spanish Ministry of Health and ISCIII (co-financed by Fondos FEDER)</Agency><Country/></Grant><Grant><GrantID>"Molecular stratification of patients with giant cell arteritis to tailor glucocorticoid and tocili-zumab therapy (START Project)"</GrantID><Agency>FOREUM, Foundation for Research in Rheumatology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084882">P-selectin ligand protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065206" MajorTopicYN="Y">Extracellular Traps</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NETs</Keyword><Keyword MajorTopicYN="N">P-selectin</Keyword><Keyword MajorTopicYN="N">PSGL-1</Keyword><Keyword MajorTopicYN="N">SLE pathogenesis</Keyword><Keyword MajorTopicYN="N">neutrophils</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37047117</ArticleId><ArticleId IdType="pmc">PMC10093849</ArticleId><ArticleId IdType="doi">10.3390/ijms24076144</ArticleId><ArticleId IdType="pii">ijms24076144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prame Kumar K., Nicholls A.J., Wong C.H.Y. Partners in crime: Neutrophils and monocytes/macrophages in inflammation and disease. Cell Tissue Res. 2018;371:551&#x2013;565. doi: 10.1007/s00441-017-2753-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-017-2753-2</ArticleId><ArticleId IdType="pmc">PMC5820413</ArticleId><ArticleId IdType="pubmed">29387942</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532&#x2013;1535. doi: 10.1126/science.1092385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092385</ArticleId><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorner T., Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344&#x2013;2358. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna G., Brennan M.T. Systemic lupus erythematosus: Epidemiology, pathophysiology, manifestations, and management. Dent. Clin. N. Am. 2013;57:631&#x2013;655. doi: 10.1016/j.cden.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cden.2013.06.003</ArticleId><ArticleId IdType="pubmed">24034070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim A., Furnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., Herrmann M., Voll R.E., Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA. 2010;107:9813&#x2013;9818. doi: 10.1073/pnas.0909927107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId><ArticleId IdType="pmc">PMC2906830</ArticleId><ArticleId IdType="pubmed">20439745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fresneda Alarcon M., McLaren Z., Wright H.L. Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O. Front. Immunol. 2021;12:649693. doi: 10.3389/fimmu.2021.649693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.649693</ArticleId><ArticleId IdType="pmc">PMC7969658</ArticleId><ArticleId IdType="pubmed">33746988</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden M., van den Hoogen L.L., Westerlaken G.H.A., Fritsch-Stork R.D.E., van Roon J.A.G., Radstake T., Meyaard L. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology. 2018;57:1228&#x2013;1234. doi: 10.1093/rheumatology/key067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key067</ArticleId><ArticleId IdType="pubmed">29608758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M., Bonanni A., Petretto A., Vaglio A., Pratesi F., Santucci L., Migliorini P., Bertelli R., Galetti M., Belletti S., et al. Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. J. Rheumatol. 2019;47:377&#x2013;386. doi: 10.3899/jrheum.181232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.181232</ArticleId><ArticleId IdType="pmc">PMC6917988</ArticleId><ArticleId IdType="pubmed">31092713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tvaroska I., Selvaraj C., Koca J. Selectins-The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules&#x2014;A Review. Molecules. 2020;25:2835. doi: 10.3390/molecules25122835.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25122835</ArticleId><ArticleId IdType="pmc">PMC7355470</ArticleId><ArticleId IdType="pubmed">32575485</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRogatis J.M., Viramontes K.M., Neubert E.N., Tinoco R. PSGL-1 Immune Checkpoint Inhibition for CD4(+) T Cell Cancer Immunotherapy. Front. Immunol. 2021;12:636238. doi: 10.3389/fimmu.2021.636238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.636238</ArticleId><ArticleId IdType="pmc">PMC7940186</ArticleId><ArticleId IdType="pubmed">33708224</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers W.S., Tang J., Shaw G.D., Camphausen R.T. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell. 2000;103:467&#x2013;479. doi: 10.1016/S0092-8674(00)00138-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)00138-0</ArticleId><ArticleId IdType="pubmed">11081633</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinoco R., Otero D.C., Takahashi A.A., Bradley L.M. PSGL-1: A New Player in the Immune Checkpoint Landscape. Trends Immunol. 2017;38:323&#x2013;335. doi: 10.1016/j.it.2017.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2017.02.002</ArticleId><ArticleId IdType="pmc">PMC5411281</ArticleId><ArticleId IdType="pubmed">28262471</ArticleId></ArticleIdList></Reference><Reference><Citation>Urzainqui A., Serrador J.M., Viedma F., Yanez-Mo M., Rodriguez A., Corbi A.L., Alonso-Lebrero J.L., Luque A., Deckert M., Vazquez J., et al. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity. 2002;17:401&#x2013;412. doi: 10.1016/S1074-7613(02)00420-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(02)00420-X</ArticleId><ArticleId IdType="pubmed">12387735</ArticleId></ArticleIdList></Reference><Reference><Citation>Negoro P.E., Xu S., Dagher Z., Hopke A., Reedy J.L., Feldman M.B., Khan N.S., Viens A.L., Alexander N.J., Atallah N.J., et al. Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Candida Species. mBio. 2020;11:e02043-19. doi: 10.1128/mBio.02043-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02043-19</ArticleId><ArticleId IdType="pmc">PMC7218286</ArticleId><ArticleId IdType="pubmed">32398316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nani S., Fumagalli L., Sinha U., Kamen L., Scapini P., Berton G. Src family kinases and Syk are required for neutrophil extracellular trap formation in response to beta-glucan particles. J. Innate Immun. 2014;7:59&#x2013;73. doi: 10.1159/000365249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365249</ArticleId><ArticleId IdType="pmc">PMC6951106</ArticleId><ArticleId IdType="pubmed">25277753</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Xu X., Lv K., Zheng G., Wang H., Chen S., Huang L., Liu Y., Zhang Y., Tang Z., et al. Asebogenin suppresses thrombus formation via inhibition of Syk phosphorylation. Br. J. Pharmacol. 2023;180:287&#x2013;307. doi: 10.1111/bph.15964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15964</ArticleId><ArticleId IdType="pubmed">36166754</ArticleId></ArticleIdList></Reference><Reference><Citation>Urzainqui A., Martinez del Hoyo G., Lamana A., de la Fuente H., Barreiro O., Olazabal I.M., Martin P., Wild M.K., Vestweber D., Gonzalez-Amaro R., et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J. Immunol. 2007;179:7457&#x2013;7465. doi: 10.4049/jimmunol.179.11.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.11.7457</ArticleId><ArticleId IdType="pubmed">18025190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Andrade N., Lamana A., Sancho D., Gisbert J.P., Gonzalez-Amaro R., Sanchez-Madrid F., Urzainqui A. P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J. Pathol. 2011;224:212&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">21432853</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Frias A., Gonzalez-Tajuelo R., Nunez-Andrade N., Tejedor R., Garcia-Blanco M.J., Vicente-Rabaneda E., Castaneda S., Gamallo C., Silvan J., Esteban-Villafruela A., et al. Development of an autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice. Arthritis Rheumatol. 2014;66:3178&#x2013;3189. doi: 10.1002/art.38808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38808</ArticleId><ArticleId IdType="pubmed">25132671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Tajuelo R., Silvan J., Perez-Frias A., de la Fuente-Fernandez M., Tejedor R., Espartero-Santos M., Vicente-Rabaneda E., Juarranz A., Munoz-Calleja C., Castaneda S., et al. P-Selectin preserves immune tolerance in mice and is reduced in human cutaneous lupus. Sci. Rep. 2017;7:41841. doi: 10.1038/srep41841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41841</ArticleId><ArticleId IdType="pmc">PMC5288776</ArticleId><ArticleId IdType="pubmed">28150814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Xie C., Wang H.W., Zhou X.J., Schwartz N., Calixto S., Mackay M., Aranow C., Putterman C., Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 2007;179:7166&#x2013;7175. doi: 10.4049/jimmunol.179.10.7166.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.10.7166</ArticleId><ArticleId IdType="pubmed">17982109</ArticleId></ArticleIdList></Reference><Reference><Citation>Etulain J., Martinod K., Wong S.L., Cifuni S.M., Schattner M., Wagner D.D. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126:242&#x2013;246. doi: 10.1182/blood-2015-01-624023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-01-624023</ArticleId><ArticleId IdType="pmc">PMC4497964</ArticleId><ArticleId IdType="pubmed">25979951</ArticleId></ArticleIdList></Reference><Reference><Citation>Carestia A., Kaufman T., Rivadeneyra L., Landoni V.I., Pozner R.G., Negrotto S., D&#x2019;Atri L.P., G&#xf3;mez R.M., Schattner M. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J. Leukoc. Biol. 2015;99:153&#x2013;162. doi: 10.1189/jlb.3A0415-161R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.3A0415-161R</ArticleId><ArticleId IdType="pubmed">26320263</ArticleId></ArticleIdList></Reference><Reference><Citation>Maugeri N., Campana L., Gavina M., Covino C., De Metrio M., Panciroli C., Maiuri L., Maseri A., D&#x2019;Angelo A., Bianchi M.E., et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J. Thromb. Haemost. 2014;12:2074&#x2013;2088. doi: 10.1111/jth.12710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12710</ArticleId><ArticleId IdType="pubmed">25163512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Sevillano E., Urzainqui A., de Andres B., Gonzalez-Tajuelo R., Domenech M., Gonzalez-Camacho F., Sanchez-Madrid F., Brown J.S., Garcia E., Yuste J. PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease. PLoS Pathog. 2016;12:e1005500. doi: 10.1371/journal.ppat.1005500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005500</ArticleId><ArticleId IdType="pmc">PMC4790886</ArticleId><ArticleId IdType="pubmed">26975045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestebroer J., Poppelier M.J., Ulfman L.H., Lenting P.J., Denis C.V., van Kessel K.P., van Strijp J.A., de Haas C.J. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood. 2007;109:2936&#x2013;2943. doi: 10.1182/blood-2006-06-015461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-06-015461</ArticleId><ArticleId IdType="pubmed">17132726</ArticleId></ArticleIdList></Reference><Reference><Citation>Troese M.J., Carlyon J.A. Anaplasma phagocytophilum dense-cored organisms mediate cellular adherence through recognition of human P-selectin glycoprotein ligand 1. Infect. Immun. 2009;77:4018&#x2013;4027. doi: 10.1128/IAI.00527-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00527-09</ArticleId><ArticleId IdType="pmc">PMC2738047</ArticleId><ArticleId IdType="pubmed">19596771</ArticleId></ArticleIdList></Reference><Reference><Citation>Herron M.J., Nelson C.M., Larson J., Snapp K.R., Kansas G.S., Goodman J.L. Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. Science. 2000;288:1653&#x2013;1656. doi: 10.1126/science.288.5471.1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.288.5471.1653</ArticleId><ArticleId IdType="pubmed">10834846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 2009;15:794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., He S., Waheed A.A., Dabbagh D., Zhou Z., Trinite B., Wang Z., Yu J., Wang D., Li F., et al. PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. Proc. Natl. Acad. Sci. USA. 2020;117:9537&#x2013;9545. doi: 10.1073/pnas.1916054117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1916054117</ArticleId><ArticleId IdType="pmc">PMC7196789</ArticleId><ArticleId IdType="pubmed">32273392</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Song Y., Zhang S., Diao M., Huang S., Li S., Tan X. PSGL-1 inhibits HIV-1 infection by restricting actin dynamics and sequestering HIV envelope proteins. Cell Discov. 2020;6:53&#x2013;68. doi: 10.1038/s41421-020-0184-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0184-9</ArticleId><ArticleId IdType="pmc">PMC7400672</ArticleId><ArticleId IdType="pubmed">32802403</ArticleId></ArticleIdList></Reference><Reference><Citation>He S., Waheed A.A., Hetrick B., Dabbagh D., Akhrymuk I.V., Kehn-Hall K., Freed E.O., Wu Y. PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity. Viruses. 2020;13:46. doi: 10.3390/v13010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010046</ArticleId><ArticleId IdType="pmc">PMC7824426</ArticleId><ArticleId IdType="pubmed">33396594</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadtmann A., Germena G., Block H., Boras M., Rossaint J., Sundd P., Lefort C., Fisher C.I., Buscher K., Gelschefarth B., et al. The PSGL-1-L-selectin signaling complex regulates neutrophil adhesion under flow. J. Exp. Med. 2013;210:2171&#x2013;2180. doi: 10.1084/jem.20130664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20130664</ArticleId><ArticleId IdType="pmc">PMC3804951</ArticleId><ArticleId IdType="pubmed">24127491</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlar R.A., Husain S. The enigmas of the lupus anticoagulant: Mechanisms, diagnosis, and management. Curr. Rheumatol. Rep. 2008;10:74&#x2013;80. doi: 10.1007/s11926-008-0013-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-008-0013-x</ArticleId><ArticleId IdType="pubmed">18457616</ArticleId></ArticleIdList></Reference><Reference><Citation>Larosa M., Le Guern V., Guettrot-Imbert G., Morel N., Abisror N., Morati-Hafsaoui C., Orquevaux P., Diot E., Doria A., Sarrot-Reynauld F., et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: The French GR2 study. Rheumatology. 2022;61:3657&#x2013;3666. doi: 10.1093/rheumatology/keab943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab943</ArticleId><ArticleId IdType="pmc">PMC9434141</ArticleId><ArticleId IdType="pubmed">35015828</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong D.J., Park D.D., Park S.S., Haller C.A., Chen J., Dai E., Liu L., Mandhapati A.R., Eradi P., Dhakal B., et al. A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis. Blood. 2021;138:1182&#x2013;1193. doi: 10.1182/blood.2020009428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020009428</ArticleId><ArticleId IdType="pmc">PMC8570056</ArticleId><ArticleId IdType="pubmed">33945603</ArticleId></ArticleIdList></Reference><Reference><Citation>Yago T., Liu Z., Ahamed J., McEver R.P. Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice. Blood. 2018;132:1426&#x2013;1437. doi: 10.1182/blood-2018-05-850859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-05-850859</ArticleId><ArticleId IdType="pmc">PMC6161769</ArticleId><ArticleId IdType="pubmed">30068506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Knight J.S., Hodgin J.B., Wang J., Guo C., Kleiman K., Eitzman D.T. Psgl-1 Deficiency is Protective against Stroke in a Murine Model of Lupus. Sci. Rep. 2016;6:28997. doi: 10.1038/srep28997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28997</ArticleId><ArticleId IdType="pmc">PMC4928054</ArticleId><ArticleId IdType="pubmed">27357136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Diaz C., Varela-Trinidad G.U., Munoz-Sanchez G., Solorzano-Castanedo K., Avila-Arrezola K.E., Iniguez-Gutierrez L., Delgado-Rizo V., Fafutis-Morris M. To Trap a Pathogen: Neutrophil Extracellular Traps and Their Role in Mucosal Epithelial and Skin Diseases. Cells. 2021;10:1469. doi: 10.3390/cells10061469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061469</ArticleId><ArticleId IdType="pmc">PMC8230648</ArticleId><ArticleId IdType="pubmed">34208037</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou E., Vassilopoulos D., Boletis J., Boumpas D.T. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun. Rev. 2019;18:751&#x2013;760. doi: 10.1016/j.autrev.2019.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.06.011</ArticleId><ArticleId IdType="pubmed">31181324</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker S.R., Mehta-D&#x2019;souza P., Zhang N., Klopocki A.G., Shao B., McEver R.P. Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mice. Blood. 2017;130:181&#x2013;191. doi: 10.1182/blood-2017-02-770479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-02-770479</ArticleId><ArticleId IdType="pmc">PMC5510792</ArticleId><ArticleId IdType="pubmed">28515093</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRogatis J.M., Viramontes K.M., Neubert E.N., Henriquez M.L., Guerrero-Juarez C.F., Tinoco R. Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma. Cancer Immunol. Res. 2022;10:612&#x2013;625. doi: 10.1158/2326-6066.CIR-21-0690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-21-0690</ArticleId><ArticleId IdType="pmc">PMC9064985</ArticleId><ArticleId IdType="pubmed">35303066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pego-Reigosa J.M., Nicholson L., Pooley N., Langham S., Embleton N., Marjenberg Z., Barut V., Desta B., Wang X., Langham J., et al. The risk of infections in adult patients with systemic lupus erythematosus: Systematic review and meta-analysis. Rheumatology. 2021;60:60&#x2013;72. doi: 10.1093/rheumatology/keaa478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa478</ArticleId><ArticleId IdType="pmc">PMC7785308</ArticleId><ArticleId IdType="pubmed">33099651</ArticleId></ArticleIdList></Reference><Reference><Citation>Braegelmann C., Holzel M., Ludbrook V., Dickson M., Turan N., Ferring-Schmitt S., Sternberg S., Bieber T., Kuhn A., Wenzel J. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp. Dermatol. 2016;25:375&#x2013;379. doi: 10.1111/exd.12986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.12986</ArticleId><ArticleId IdType="pubmed">26910509</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinblatt M.E., Kavanaugh A., Genovese M.C., Musser T.K., Grossbard E.B., Magilavy D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 2010;363:1303&#x2013;1312. doi: 10.1056/NEJMoa1000500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1000500</ArticleId><ArticleId IdType="pubmed">20879879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunwar S., Devkota A.R., Ghimire D.K. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: A meta-analysis of randomized controlled trials. Rheumatol. Int. 2016;36:1077&#x2013;1087. doi: 10.1007/s00296-016-3482-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3482-7</ArticleId><ArticleId IdType="pubmed">27113955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630&#x2013;640. doi: 10.1002/art.1780350606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung J.C., Brown M.L. Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. Volume 2. University of New Mexico; Albuquerque, NM, USA: 1993. Radiopharmaceuticals for Imaging of Infectious and Inflammatory Lesions; pp. 1&#x2013;25.</Citation></Reference><Reference><Citation>Thakur M.L., Seifert C.L., Madsen M.T., McKenney S.M., Desai A.G., Park C.H. Neutrophil labeling: Problems and pitfalls. Semin. Nucl. Med. 1984;14:107&#x2013;117. doi: 10.1016/S0001-2998(84)80024-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0001-2998(84)80024-0</ArticleId><ArticleId IdType="pubmed">6427928</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorson L.M., Turkalj A., Hung J.C. In vitro evaluation of neutrophil viability after exposure to a hypotonic medium. Nucl. Med. Commun. 1995;16:615&#x2013;620. doi: 10.1097/00006231-199507000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006231-199507000-00014</ArticleId><ArticleId IdType="pubmed">7478401</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvan J., Gonzalez-Tajuelo R., Vicente-Rabaneda E., Perez-Frias A., Espartero-Santos M., Munoz-Callejas A., Garcia-Lorenzo E., Gamallo C., Castaneda S., Urzainqui A. Deregulated PSGL-1 Expression in B Cells and Dendritic Cells May Be Implicated in Human Systemic Sclerosis Development. J. Investig. Dermatol. 2018;138:2123&#x2013;2132. doi: 10.1016/j.jid.2018.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2018.04.003</ArticleId><ArticleId IdType="pubmed">29689251</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneck T., Mergani A., Clever S., Seidler A.E., Brogden G., Runft S., Baumgartner W., Branitzki-Heinemann K., von Kockritz-Blickwede M. Formation of Neutrophil Extracellular Traps by Reduction of Cellular Cholesterol Is Independent of Oxygen and HIF-1alpha. Int. J. Mol. Sci. 2022;23:3195. doi: 10.3390/ijms23063195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063195</ArticleId><ArticleId IdType="pmc">PMC8954871</ArticleId><ArticleId IdType="pubmed">35328617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T., Tengstrom F.C., Kamerling S.W., Pusey C.D., Scherer H.U., Toes R.E., Rabelink T.J., van Kooten C., Teng Y.K. A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. Autoimmun. Rev. 2016;15:577&#x2013;584. doi: 10.1016/j.autrev.2016.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.02.018</ArticleId><ArticleId IdType="pubmed">26925759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavillet M., Martinod K., Renella R., Harris C., Shapiro N.I., Wagner D.D., Williams D.A. Flow cytometric assay for direct quantification of neutrophil extracellular traps in blood samples. Am. J. Hematol. 2015;90:1155&#x2013;1158. doi: 10.1002/ajh.24185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24185</ArticleId><ArticleId IdType="pmc">PMC4715743</ArticleId><ArticleId IdType="pubmed">26347989</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S., Shimizu S., Matsuo J., Nishibata Y., Kusunoki Y., Hattanda F., Shida H., Nakazawa D., Tomaru U., Atsumi T., et al. Measurement of NET formation in vitro and in vivo by flow cytometry. Cytometry A. 2017;91:822&#x2013;829. doi: 10.1002/cyto.a.23169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23169</ArticleId><ArticleId IdType="pmc">PMC5601186</ArticleId><ArticleId IdType="pubmed">28715618</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneck E., Mallek F., Schiederich J., Kramer E., Markmann M., Hecker M., Sommer N., Weissmann N., Pak O., Michel G., et al. Flow Cytometry-Based Quantification of Neutrophil Extracellular Traps Shows an Association with Hypercoagulation in Septic Shock and Hypocoagulation in Postsurgical Systemic Inflammation-A Proof-of-Concept Study. J. Clin. Med. 2020;9:174. doi: 10.3390/jcm9010174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010174</ArticleId><ArticleId IdType="pmc">PMC7019434</ArticleId><ArticleId IdType="pubmed">31936385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S., Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006;224:213&#x2013;232. doi: 10.1111/j.1365-2818.2006.01706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2006.01706.x</ArticleId><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>